Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep

seekingalpha2021-03-09

Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

maltose123
2021-03-09
maltose123
mdndhd
Jerkkid
2021-03-09
Jerkkid
Good!

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168910610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-03-09 14:48","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1168910610","market":"us","top_or_hot":-1,"title":"Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep","media":"seekingalpha","content":"<div>\n<p>Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in...</p>\n\n<a href=\"https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-09 14:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in...</p>\n\n<a href=\"https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep","article_id":"1168910610","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168910610","pubTimestamp":1615272511,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from t","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华","MLLCF":"Molecular Partners AG"},"translate_title":"Novartis,Molecular Partners报告新冠病毒抗病毒疗法ensovibep的早期阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLLCF":0.9,"NVS":0.9},"content_text":"Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.Healthy volunteers were randomized 3:1 to receive ensovibep or placebo, respectively.Two dosing cohorts with 8 patients per dose cohort have been fully enrolled and received a single infusion of 3mg or 9mg per kilogram body weight.In each of these cohorts, ensovibep was seen to be safe and well tolerated, with no significant adverse events reported.Preliminary results showed extended exposure of the DARPin candidate in serum, with a half-life of 2-3 weeks.These data support advanced plans for additional clinical work in positively diagnosed patients.The companies looks forward to initiate phase 2/3 global registration study, early in Q2.Per protocol, a third cohort at a 20mg per kilogram dose level has been planned.In October 2020, Molecular Partners and Novartis collaborated to developtwo DARPin therapies for COVID-19.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":329457469,"gmtCreate":1615274030751,"gmtModify":1704780419133,"author":{"id":"3578010145980988","authorId":"3578010145980988","name":"maltose123","avatar":"https://static.tigerbbs.com/071a4309a84b94aafc5b5d2c0fec025b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578010145980988","authorIdStr":"3578010145980988"},"htmlText":"&nbsp;mdndhd","listText":"&nbsp;mdndhd","text":"mdndhd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329457469","repostId":1168910610,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":329427540,"gmtCreate":1615272877280,"gmtModify":1704780405052,"author":{"id":"3574728819925158","authorId":"3574728819925158","name":"Jerkkid","avatar":"https://static.tigerbbs.com/48b72dba4956ea1e95c37b60daec61ac","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574728819925158","authorIdStr":"3574728819925158"},"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329427540","repostId":1168910610,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":9,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168910610"}